Truist Financial Corp Geron Corp Transaction History

Truist Financial Corp

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2021 May 17, 2021	SELL	$1.52 - $2.1 $15,200 - $21,000	-10,000 Closed	0 $0
Q4 2020 Nov 19, 2021	SELL	$1.55 - $2.05 $37,365 - $49,419	-24,107 Reduced 70.68%	10,000 $16,000
Q4 2020 Feb 18, 2021	BUY	$1.55 - $2.05 $37,365 - $49,419	24,107 Added 241.07%	34,107 $54,000
Q4 2019 Feb 14, 2020	BUY	$1.27 - $1.54 $12,700 - $15,400	10,000 New	10,000 $14,000

275

491M

1.87M

690K

Ticker GERN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 377,819,008
Market Cap $1.54B
Description
Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in hemat...

Get notified when there are updates to the investment portfolio of Truist Financial Corp, based on Form 13F filings with the SEC.

Stay updated on Truist Financial Corp with notifications on news.